Results 121 to 130 of about 3,993,592 (301)

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar   +6 more
wiley   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl   +14 more
wiley   +1 more source

A case report: new-onset nummular headache after stenting of the middle cerebral artery

open access: yesBMC Neurology
Background Nummular headache (NH) is categorized as a primary headache in the International Classification of Headache Disorders, Third edition (ICHD-3) diagnostic criteria, but there are secondary etiologies as well.
Yuanyuan Liu   +6 more
doaj   +1 more source

Headache and Atypical Presentation of Motor Disorders in A Paraneoplastic Myasthenic Syndrome Secondary to Thymoma: A Case Report [PDF]

open access: yesJournal of Clinical and Experimental Investigations, 2022
Gabriele Cioni   +3 more
openaire   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz   +7 more
wiley   +1 more source

Pectoralis Minor Tenotomy with Occasional Secondary Neurolysis Significantly Reduces Self-Reported Pain and Headaches Across Heterogenous Chronic Pain Disorders of the Upper Limb

open access: yesMedicina
Background and Objectives: Many patients suffer from chronic pain of the shoulder, neck, upper back, and/or arm. They may be diagnosed with fibromyalgia, complex regional pain syndrome, myofascial pain, thoracic outlet, subacromial pain, cervical radiculopathy, cervicogenic headaches, post-mastectomy pain, and/or occupational shoulder disorder.
Ketan Sharma, James M. Friedman
openaire   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano   +6 more
wiley   +1 more source

Network analysis of headache diagnoses using international classification of headache disorders, 3rd edition

open access: yesFrontiers in Neurology
Background and objectiveThe International Classification of Headache Disorders, Third Edition (ICHD-3), significantly influences clinicians’ understanding of headache disorders.
Pengfei Zhang, Thomas Berk, Thomas Berk
doaj   +1 more source

The Relationship Between Temporomandibular disorders and Headache [PDF]

open access: yes, 2009
Temporomandibular disorders (TMD) is a collective term embracing a number of clinical problems that involving the masticatory musculature, the TMJ and associated structures, or both.
김성택
core  

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

Home - About - Disclaimer - Privacy